Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 8/20 | 0.38 |
| ▸ | TTK | P33981 | 2/20 | 0.32 |
| ▸ | JAK2 | O60674 | 9/20 | 0.31 |
| ▸ | JAK1 | P23458 | 9/20 | 0.31 |
| ▸ | LCK | P06239 | 4/20 | 0.31 |
| ▸ | AURKB | Q96GD4 | 4/20 | 0.31 |
| ▸ | CCNT1 | O60563 | 1/20 | 0.30 |
| ▸ | CDK9 | P50750 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formic Acid SCHEMBL25170364 | 0.97 | PTK6 (0.36) | PTK6TTKJAK2JAK1 | |
| SCHEMBL32675701 | 0.94 | PTK6 (0.32) | PTK6TTK | |
| SCHEMBL24112318 | 0.94 | PTK6 (0.32) | PTK6TTK | |
| SCHEMBL24112424 | 0.92 | PTK6 (0.33) | PTK6TTK | |
| SCHEMBL32675703 | 0.92 | PTK6 (0.33) | PTK6TTK | |
| SCHEMBL25176130 | 0.91 | PTK6 (0.45) | PTK6TTKJAK2JAK1LCK | |
| Trifluoroacetic Acid SCHEMBL30385687 | 0.90 | TTK (0.32) | PTK6TTK | |
| Hydrochloric Acid SCHEMBL25173472 | 0.90 | PTK6 (0.45) | PTK6TTKJAK2JAK1LCK | |
| SCHEMBL24112395 | 0.90 | PTK6 (0.40) | PTK6TTKJAK2JAK1LCK | |
| Iodide SCHEMBL25176490 | 0.89 | PTK6 (0.36) | PTK6TTKJAK2JAK1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-05-11 | — | — | US | disclosed |
| WO-2021249896-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-12-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230141600-A1 | IMIDAZOPYRAZINE DERIVATIVES | IKZF3, RRP15, IK | PTK6 925/4885TTK 4336/4885JAK2 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.